Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.31 (
AMP-activated protein kinase
)
13,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cytochrome P450 2J2
(
CYP2J2
) epoxygenase converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) that exert multiple biological effects in the cardiovascular system and in various human solid cancers. However, it is unknown whether this enzyme is expressed or plays any role in malignant hematological diseases. In this study, we found strong and highly selective
CYP2J2
expression in five human-derived malignant hematological cell lines and in leukemia cells from peripheral blood and bone marrow in 36 of 42 patients (86%) with malignant hematologic diseases. Furthermore, increased levels of EETs were detected in urine and blood samples from these patients. Addition of exogenous EET or
CYP2J2
overexpression in cultured human-derived malignant hematologic cell lines markedly accelerated proliferation and attenuated apoptosis. Addition of the selective
CYP2J2
inhibitor compound 26 (C26; 1-[4-(vinyl) phenyl]-4-[4-(diphenyl-hydroxymethyl)-piperidinyl]-butanone hydrochloride) inhibited cell proliferation and increased apoptosis, an effect that was significantly reversed by EET.
CYP2J2
overexpression and exogenous EET activated
AMP-activated protein kinase
, c-Jun NH(2)-terminal kinase, and phosphatidylinositol 3-kinase/Akt signaling pathways, and increased epidermal growth factor receptor phosphorylation levels.
CYP2J2
overexpression also enhanced malignant xenograft growth, which was efficiently inhibited by oral administration of C26 in Tie2-
CYP2J2
transgenic mice and in severe combined immunodeficiency (SCID) xenograft mice. Together, these results suggest that
CYP2J2
plays a key role in the pathogenesis of human hematologic malignant diseases. Selective inhibition of
CYP2J2
may be a promising therapeutic strategy for these conditions.
...
PMID:Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. 2103 Apr 85